



ASX ANNOUNCEMENT

Vitura Business Transformation establishes ~\$2.7M annualised cost savings and positions company for further revenue growth

28 APRIL 2026

Melbourne, Australia – Vitura Health Limited (ASX: VIT) (**Vitura and the Company**), a leading digital health platform business, today provides an update on its business transformation initiatives during Quarter 3 FY2026.

Commercial Momentum

The Company has maintained focus on revenue growth and operational performance across its core businesses:

- As announced on 17 March 2026, the new distribution agreement signed with MedReleaf - one of Australia's top therapeutic product suppliers - is expected to contribute up to \$15m in incremental revenue over time as volumes scale through the Canview platform.
- A renewed focus on improving pricing and rebates, expected to deliver approximately \$1m annualised gross profit improvement and be in place by the end of June.
- Patient acquisition and retention numbers for Candor tracking to finish H2 FY2026 nearly 25% up on H1 FY2026, and the introduction of a Quit Smoking service in Quarter 4 FY2026 expected to support continued performance.

Operating Leverage Reset

The Company has implemented several initiatives to simplify operations, align its cost base with core business activities and drive a fit-for-purpose business model, including:

- A personnel restructure with the displacement on non-value add activities and roles, resulting in ~\$2.0m of annualised saving; and
- A general reduction in discretionary spend, lease reviews and joint venture operations, resulting in ~\$0.7m of annualised savings

As a result of the operating leverage reset, the Company has realised annualised cost savings of approximately \$2.7m:

| Cost Category | Savings (Annualised) |
|-----------------|----------------------|
| Personnel costs | ~\$2.0m |
| Other costs | ~\$0.7m |
| Total | ~\$2.7m |

** Annualised. Other costs include occupancy, overheads, and JV cost realignment.*

While these initiatives establish a materially improved run-rate for the business, the financial benefits will be realised progressively. Given the timing of implementation in the second half of FY2026, most cost savings and revenue contributions will be reflected in FY2027 and beyond.

With the successful implementation of these initiatives, a Stage 2 business transformation project will be undertaken in FY2027 to further streamline operations with a more efficient and effective cost structure.

Vitura Chief Revenue Officer Ryan Tattle said:

“Since late January, Vitura has undertaken a focused reset of its cost base and operating structure. The delivery of approximately \$2.7 million in annualised cost savings reflects decisive action to align the business more with its core activities and improve overall efficiency.”

“Importantly, these changes position the business with a structurally lower cost base and improved operating leverage. While the majority of financial benefits will be realised over FY2027 as initiatives fully mature, we are already seeing early operational improvements across key segments.”

ENDS

Authorised by – The Board of Vitura Health Limited.

Contact**Vitura Health Limited**

Robert Iervasi
Chair
1300 799 491
info@vitura.com.au

Media enquiries

Dieter Lehmann
Nominis Communications
+61 427 672 995
dieter@nominis.me

Forward-looking statements

This announcement includes forward-looking statements which may be identified by words such as 'anticipates', 'believes', 'expects', 'intends', 'may', 'will', 'could', or 'should' and other similar words that involve risks and uncertainties. These forward-looking statements are based on the Company's expectations and beliefs concerning future events as at the date of this announcement. Forward-looking statements are necessarily subject to risks, uncertainties, and other factors, many of which are outside the control of the Company, which could cause actual results to differ materially from such statements. The Company makes no undertaking to update or revise the forward-looking statements made in this announcement to reflect any change in circumstances or events after the date of this announcement.

About Vitura Health Limited (ASX: VIT)

- www.vitura.com.au
Vitura Health Limited is diversified digital health business listed on the ASX (ASX: VIT) and, via its subsidiaries, operates the following businesses:
- www.burleighheadscannabis.com
Burleigh Heads Cannabis operates the market leading prescriber, patient, pharmacy, and supplier online ecosystem, Canview, which sells and distributes roughly 600 therapeutic product and device SKUs within Australia from roughly 70 international and domestic brands.
- www.canview.com.au
Canview was developed to be a complete end-to-end healthcare ecosystem designed to provide doctors, pharmacists, and patients with a simple and cost-effective way to facilitate the treatment of patients with increased efficiency and compliance. The Canview system is based on a medicines wholesaling platform which seamlessly brings together several disparate SAAS (software-as-a-service) providers including inventory control, invoicing, customer management, reporting and analytics, all linked together through customised integration software owned and operated by Vitura. Underpinning the suite of SAAS elements are several bespoke, internally generated operating procedures and intellectual property assets, supported by the Canview customer support and infield customer engagement teams. Through the in-house integration of the different elements which together make up Canview, the platform provides the best user experience in the industry.

Canview provides Australian doctors with the ability to integrate their patient management systems directly with the platform and to use their patient information to generate electronic prescriptions within the Canview platform, without the need to input the patient's details. Prescriptions are then sent directly

to the Canview patient app where patients can manage their treatment and submit the prescription and subsequent repeats to one of the roughly 4,700 Australian pharmacies with accounts on Canview for dispensing.

While the Company's current operations focus on the sale and distribution of medicinal cannabis products, Vitura is fully licensed and equipped, via its two state-of-the-art distribution centres in Melbourne and the Gold Coast, to distribute all products under Schedules 2, 3, 4, 8 and 9. The establishment during the year of the Company's joint venture to distribute psychedelic products, including MDMA and Psilocybin, is a timely example of the many opportunities that the Company believes can be seamlessly integrated into its existing digital health platform business.

- www.doctorsondemand.com.au
The Company owns Doctors on Demand Pty Ltd, a nationwide 24/7 x 365 telehealth platform business that provide innovative primary health solutions to hundreds of thousands of B2C and B2B patients annually. Services include general medical consults, urgent care, medical certificates, pathology referrals, specialist referrals, men's health, women's health and medicated weight loss.
- www.cortexa.com.au
The Company owns 50% of Cortexa Pty Ltd, an incorporated joint venture with Canadian-based PharmAla Biotech (CSE: MDMA). Cortexa aims to be the leading supplier of psychedelics, GMP MDMA and GMP psilocybin, for research and therapeutic use in Australia.
- www.candor.com.au
The Company owns Candor Medical that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis and other speciality products and services.
- www.releaf.com.au
The Company owns a 42.5% equity interest in Flora Holdings Pty Ltd, a joint venture that owns and operates a series of medicinal cannabis clinics operating under the Releaf brand.
- www.cdaclinics.com.au
The Company owns CDA Clinics that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis.
- www.cannadoc.com.au
The Company owns 75.5% of Cannadoc Health Pty Ltd, a medicinal cannabis clinic business that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis.